# COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,

> **NIH NIH N01** · UNIVERSITY OF GEORGIA · 2022 · $2,229,415

## Abstract

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”) and other emerging or reemerging infectious diseases.

## Key facts

- **NIH application ID:** 10621132
- **Project number:** 75N93019C00052-P00014-9999-2
- **Recipient organization:** UNIVERSITY OF GEORGIA
- **Principal Investigator:** TED ROSS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,229,415
- **Award type:** —
- **Project period:** 2019-09-10 → 2023-05-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10621132

## Citation

> US National Institutes of Health, RePORTER application 10621132, COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, (75N93019C00052-P00014-9999-2). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10621132. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*